



Notification of the Merger of CSO-Related Subsidiary Companies

We would like to announce that, following a meeting of the board of directors on May 1st 2013, agreement has been reached on the approval of the merger of our consolidated subsidiaries Pharma Network Co., Ltd. (Bunkyo-ku, Tokyo, Representative Director: Ezura Kataoka, henceforth termed 'Pharma Network') and Medical Line Co., Ltd. (Toshima-ku, Tokyo, Representative Director: Junichi Nishizuka, henceforth termed 'Medical Line').

1. Objective of the Merger

Within EPS group, CSO operations ('Contract Sales Organization', representing and undertaking marketing and sales responsibilities from pharmaceutical companies and medical equipment sales and manufacturing companies) are administered by Pharma Network (chiefly being entrusted with MR functions and their dispatch) and Medical Line (chiefly operating specialized call center functions for the drug, medical treatment and healthcare industries).

In recent years, the needs of pharmaceutical companies and medical equipment manufacture and sales companies have diversified and become more complex. Within this environment, we hope to make full use of the strengths and characteristics of these two companies, create and present a solution with extra value in the area of product sales, along with the expansion in scale that the merger will bring.

Through a strengthening of our CSO operations, as a group we aim for the further enrichment of our one-stop solution, from clinical development, to sales and post-marketing surveillance support.

2. Summary of the Businesses to be Merged

(1)Company Name	Pharma Network Co., Ltd (Merging company)	Medical Line Co., Ltd. (Merged company)
(2)Business Description	1. CSO Operations 2. Training and Development Operations 3. Fee-charging Recruitment Services 4. Other services related to those above	1. Medical Call Center Services 2. Fee-charging Recruitment Services 3. BPO Services 4. Other services related to those above.



(3)Date of Foundation	November 1997	September 2006
(4)Capital	¥433 million	¥236 million
(5) Shareholder Distribution	EPS Corporation: 95.1% TOHO HOLDINGS CO., LTD.: 4.2%	EPS Corporation: 66.1% Ant Bridge No.2 Venture Capital Secondary Investment Limited Partnership: 22.6%
(6)Name and Titles of Representatives	Representative Director & Chairman: Tomohiro Tominaga Representative Director & President: Ezura Kataoka	Representative Director & President: Junichi Nishizuka
(7)Location of Head Office	Bunkyo-ku, Tokyo	Toshima-ku, Tokyo
(8)Operating Results for the Most Recent Fiscal Year: Net sales Operating Profit Ordinary Profit Net Assets	FY September 2012 ¥3,865 million ¥575 million ¥588 million ¥1,331 million	FY September 2012 ¥2,016 million ¥100 million ¥100 million ¥408 million
(9)Number of Employees (at the end of March 2013)	352	265

3. Summary of Merger

- | | |
|-----------------------------|---|
| (1) Date of Merger | October 1st 2013 (planned) |
| (2) Method of Merger | Pharma Network to be the continuing company. |
| (3) Name after Merger | EP Medinet Co., Ltd. (provisional name) |
| (4) Principal Officials | Director & Chairman: Shinro Tashiro
Representative Director & President: Junichi Nishizuka |
| (5) Location of Head Office | Bunkyo-Ku, Tokyo |
| (6) Other Details | Details such as merger ratio, and the capital stock of the new company unconfirmed. |

4. Effects on Consolidated Business Performance in this Term

With regards to our company's consolidated results, since the merger within the consolidated group companies will take place next term on October 1st, it is anticipated that there will be no effect on the current consolidated business performance. In the event that effects on performance are anticipated, timely announcements will be made at the defined stage.